Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack

August 27, 2012

According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.

For more than a million Americans who survive a heart attack each year, doctors routinely prescribe a daily aspirin to help prevent the formation of in the arteries which can frequently lead to another heart attack. Other platelet blockers, like , which also serve this purpose, are often added for up to a year, but the scientific evidence is unclear about whether adding platelet blockers to aspirin beyond this timeframe is clinically useful. Despite such therapies, these patients have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.

"There continues to be substantial uncertainty regarding the benefit of long-term in addition to aspirin in patients with prior heart attacks," said Benjamin M. Scirica, M.D., M.P.H., investigator at the TIMI Study Group, a cardiologist at BWH, and one of the study's investigators. "This is the first study to show convincingly that continued, long-term, therapy beyond one year with more potent antiplatelet therapy reduces the risk of having another cardiovascular event." Previous studies in did not show this benefit.

Researchers from the TIMI Study Group at BWH have shown, for the first time, that adding vorapaxar, a new antiplatelet medication, on top of standard therapy which includes aspirin, is effective for long-term secondary prevention in with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 20 percent.

This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack, stroke or atherosclerotic narrowing in the arteries of the legs. Participants were randomly assigned to receive the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy. The overall trial results, which were presented and published in March 2012, demonstrated a 13 percent reduction in the risk of cardiovascular death, heart attack or stroke. These new findings focus specifically on the 17,779 patients with a prior heart attack.

Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. In addition to the benefit of reducing future cardiac events, researchers also report that this new therapy was found to increase the risk of moderate or severe bleeding in patients with prior heart attacks. Intracranial hemorrhage tended to be higher but did not differ significantly between vorapaxar than placebo (0.6 vs. 0.4 percent at 3 years),

Researchers caution that if vorapaxar becomes available for clinical use, clinicians will have to balance the antithrombotic efficacy versus the risk of bleeding for the individual patient.

"Of the groups we studied, the greatest net was observed in those patients who are less than 75 years old, have no history of stroke or transient ischemic attacks, and weigh at least 60 kilograms," said Scirica. "In this group of 14,909 patients, 84 percent of the group with prior heart attacks, vorapaxar reduced the risk of cardiovascular death, , or stroke by 25 percent and cardiovascular death alone by 27 percent."

Explore further: New class of platelet blockers proves effective in phase III trial

Related Stories

New class of platelet blockers proves effective in phase III trial

March 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...

Merck blood thinner shows mixed results: study

March 24, 2012
An experimental blood thinning drug made by the pharmaceutical giant Merck may reduce the risk of dying from a heart attack but also boosts the danger of internal bleeding, researchers said Saturday.

New platelet blocker reduces blood clots, artery-opening procedures

June 21, 2012
A new investigational platelet blocker reduces the rate of clotted arteries and the need for artery-opening revascularization procedures in the legs in people with peripheral artery disease (PAD), according to new research ...

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

September 26, 2011
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of ...

Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events

March 26, 2012
Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall ...

Recommended for you

How genes and environment interact to raise risk of congenital heart defects

October 19, 2017
Infants of mothers with diabetes have a three- to five-fold increased risk of congenital heart defects. Such developmental defects are likely caused by a combination of genetic and environmental factors. However, the molecular ...

Mouse studies shed light on how protein controls heart failure

October 18, 2017
A new study on two specially bred strains of mice has illuminated how abnormal addition of the chemical phosphate to a specific heart muscle protein may sabotage the way the protein behaves in a cell, and may damage the way ...

Newborns with trisomy 13 or 18 benefit from heart surgery, study finds

October 18, 2017
Heart surgery significantly decreases in-hospital mortality among infants with either of two genetic disorders that cause severe physical and intellectual disabilities, according to a new study by a researcher at the Stanford ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

Physically active white men at high risk for plaque buildup in arteries

October 17, 2017
White men who exercise at high levels are 86 percent more likely than people who exercise at low levels to experience a buildup of plaque in the heart arteries by middle age, a new study suggests.

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.